Allergan Plc (AGN)
$166.10 0.54 (0.33%)
16:13 EDT AGN Stock Quote Delayed 15 Minutes
Previous Close $165.56
Market Cap 65.19B
PE Ratio -32.38
Volume (Avg. Vol.) 2.98M
Day's Range 165.41 - 166.62
52-Week Range 114.27 - 197.00
Dividend & Yield 2.88 (1.73%)
AGN Stock Predictions, Articles, and Allergan Plc News
- From InvestorPlace
- From the Web
The markets are looking uneven, so investors need to pay attention to which stocks are hot and which ones are cooling off.
Pharmaceutical stocks have been on the rebound and many are raising their prices this year. What does that mean for business?
Despite their indispensable demand, pharmaceutical stocks face tough roadblocks as competition for breakthrough drugs intensifies.
The upside case for pharmaceutical stocks is building. The midterm elections results mean its unlikely drug price regulation will happen soon.
Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.
Don't be afraid of investing in down sectors. There's plenty of opportunities in the oil patch, which is why we've picked these 10 oil stocks to buy.
Drug stocks have been beaten up ever since the 2015 collapse of Valeant, but many of them are now too cheap to ignore.
The short-term outlook on AGN stock is messy due to drug pricing issues. But the long-term outlook remains promising - thanks to the company's wide moat and stable growth prospects.
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.
Teva Pharmaceuticals is quietly moving higher on the stock market for good reason: worries over pricing and the impact of competition in generics is getting clearer. Teva stock is a great long-term bet.
Axovant Sciences soared last week after AXON stock presented AXO-Lenti-PD, a gene therapy product that treats Parkinson's Disease.
Allergan (AGN) raised its quarterly and yearly outlook but the stock slumped in trading after the earnings announcement. A big write-down is hammering the stock price.
Allergan stock has slid steadily since last summer. With upside likely limited in the near-term, AGN isn't a falling knife worth catching.
RVNC has an edge with its formulation of Botox: it lasts longer. Given the little innovation in the botulinim toxin market, Revance has a real chance to succeed.
From The Street
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!